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Sickle cell disease, part 1:
Understanding the condition
Sickle cell disease (SCD) is one of the most common genetic blood disorders in the world 
and effects approximately 12 500 individuals in the UK. This article looks at the definition 
of SCD, symptoms and treatments, and practical tips to prevent sickle cell crises.
S ickle cell disease (SCD) is a group of genetic disorders that affect haemoglobin. This is the molecule in red blood cells that delivers oxygen 
to cells throughout the body. People with SCD have 
atypical haemoglobin molecules called haemoglobin S, 
which can alter red blood cells into a sickle or crescent 
shape (Serjeant and Serjeant, 2001). In Britain it is 
most common in people of African or Afro-Caribbean 
descent but may also occur in people from India, 
Pakistan, the Middle East or eastern Mediterranean. An 
estimated 12 500 individuals live with SCD in England 
(Sickle Cell Society, 2008).
Genetic inheritance
Sickle cell disease is an autosomal recessive genetic 
disorder. For the disease to manifest a person must 
inherit two copies of the sickle cell gene—­one from 
each parent. People who inherit a sickle cell gene from 
one parent and a normal gene from the other have 
a condition called sickle cell trait (Hb AS). They do 
not have the disease but they possess one of the genes 
that causes it and can therefore pass this gene to their 
children. For example, if one parent has sickle cell 
anaemia and the other is normal all of the children will 
have sickle cell trait. When both parents have sickle 
cell trait they have a 25% chance of having a baby with 
sickle cell disease at every pregnancy (Serjeant and 
Serjeant, 2001; Oni at al, 2006).
How does sickling happen?
Normal red cells are biconcave, soft and flexible. They 
maintain their shape as they pass through the capillaries 
and release oxygen to the peripheral tissues. However, when 
sickle haemoglobin releases oxygen in the peripheral tissues 
the molecules tend to stick together and form long chains or 
polymers. The polymer is a rope-like fibre that aligns with 
others to form a bundle distorting the red cell into classic 
crescent or sickled forms. The problem is not simply one of 
abnormal shape as the deformed cells are rigid. They block 
the flow of cells and interrupt the delivery of oxygen to the 
tissues causing ischemia, pain and tissue damage (Bain, 
2002; Stuart and Nagel, 2004) (Figure 1).
Types of sickle cell disease
There are different types of sickle cell disease. The most 
common are Haemoglobin SS or sickle cell anaemia, 
Haemoglobin SC disease, and Haemoglobin sickle beta-
thalassaemia (Table 1).
Thalassaemia genes produce normal haemoglobin 
but in variably reduced amounts. If the gene produces 
no normal haemoglobin, which is sickle beta zero 
thalassaemia, the condition is virtually identical to 
sickle cell anaemia. Some patients have a gene that 
produces a small amount of normal haemoglobin, 
which is sickle beta plus thalassaemia, that tends to 
result in a mild form of sickle cell disease. Sickle beta-
thalassaemia is the most common sickle syndrome seen 
in people of Mediterranean descent such as Italians, 
Greeks and Turks (Franklin, 1990; Bain, 2002; Oni et al, 
2006; Sickle Cell Society, 2008).
Symptoms
The severity of symptoms varies between patients. 
Some people have mild symptoms while others are 
frequently hospitalized for the treatment of more serious 
complications. However, the basic problem is the same; 
namely, the sickle-shaped red blood cells tend to get stuck 
in narrow blood vessels which blocks the flow of blood. 
This results in the following conditions:
Anaemia
The anaemia in sickle cell disease is caused by red cell 
destruction or haemolysis. Normally red blood cells live 
for about 120 days before new ones replace them. Sickle 
cells usually die after about 10–20 days. The bone marrow 
cannot make new red blood cells fast enough to replace 
the dying ones. Anaemia can cause shortness of breath, 
fatigue, and delayed growth and development in children. 
The rapid breakdown of red blood cells may also cause 
yellowing of the eyes and skin which are signs of jaundice 
(Franklin, 1990; Serjeant and Serjeant, 2001; Sickle cell 
Society, 2008).
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Vaso-occlusive crises (sickle cell crises)
The most common clinical manifestations are painful 
crises  as a result of blockage of small vessels and tissue 
infarction. These account for more than 90% of all 
hospital admissions (Platt et al, 1991).
There is enormous variation in the number of crises 
patients have each year. Some patients have painful crises 
less than once per year while others have as many as 10 
or more episodes (Franklin, 1990; Platt et al, 1991). An 
average sickle cell crisis usually lasts 4–7 days if there 
are no complications (Davis at al, 1997). The crisis can 
come out of nowhere or there can be some precipitating 
factors, such as dehydration, infection, stress, exposure to 
extreme temperatures, hypoxia, and strenuous exercise. 
Repeated crises ultimately result in organ damage and 
almost any organ can be affected. Other common clinical 
complications include (Stuart and Nagel, 2004; Sickle Cell 
Society, 2008):
Splenic sequestration
Sepsis, acute chest syndrome
Priapism (painful erection)
Lung disease
Leg ulcers
Avascular necrosis on the bones
Kidney damage
Gallstones
n
n
n
n
n
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Sickle cell anaemia
Sickle cell anaemia is the most common form of 
sickle cell disease and it occurs if a person inherits 
the haemoglobin S gene from both parents. This type 
tends to be the most serious of the sickle  
cell conditions. 
Haemoglobin SC disease
Haemoglobin SC disease occurs if a person inherits 
Hb S from one parent and Hb C from another. On 
average patients with haemoglobin SC disease 
have milder symptoms than do those with sickle cell 
anaemia. Some people with haemoglobin SC disease 
have a condition that is as severe as any patient with 
sickle cell anaemia. 
Sickle beta-thalassaemia
Sickle beta-thalassaemia occurs if a person inherits a 
gene for haemoglobin S from one parent and a gene 
for beta-thalassaemia from the other.
Table 1. Examples of  
some common types  
of sickle cell disease
Healthy red blood cell, circular 
in shape with a biconcave 
profile, consisting of an elastic 
framework in which 
haemoglobin is embedded
Normal lifespan is 
approximately 120 days
Sickle shaped red blood cell
Haemoglobin is long and 
rigid.  Lifespan is 
approximately 10 days
Normal free flowing 
red blood cells 
throughout the 
circulation
Sickle cells becoming 
lodged, imparing blood 
flow within the circulation 
and other major organs
Blood vessel Blood vessel
Figure 1. Examples of blodd vessels with normal red blood cells and sickle shaped red blood cells.
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Proliferative retinopathy leading to progressive 
visual loss
Stroke.
Treatment
Sickle cell disease does not have a widely available cure. 
However, treatments for the symptoms and complications 
of the disease exist. Bone marrow transplant may offer 
a cure in a small number of cases. There is some 
research about gene correction in sickle cell disease 
(Vichinsky, 2002; Perumbeti and Malik, 2010). Treatment 
of the complications often includes antibiotics, pain 
management, intravenous fluids and blood transfusion. 
Like all patients with chronic diseases they are best 
managed in a comprehensive multi-disciplinary 
programme of care.
Prevent infections
In general children and adults with sickle cell anaemia 
are more vulnerable to infections and have a harder 
time fighting them off. This is the result of spleen 
damage from sickled red cells, which prevents it from 
destroying bacteria in the blood. Giving oral penicillin 
twice a day beginning at 2 months old can prevent 
pneumococcal infection and early death. Vaccinations 
against pneumococcal infections, meningitis, hepatitis 
and flu are also important (Oni et al, 2006).
Pain management
Pain caused by sickle cell disease can be acute, chronic 
or a mixture of the two, and patients should be treated 
accordingly. Acute vaso-occlusive pain is the most 
common pain in sickle cell disease and is usually treated 
with a combination of anti-inflammatory agents and 
opioid or non-opioid analgesics. There are no objective 
measurements of the severity of pain and analgesia should 
be titrated against the patient’s reported pain. The severity 
of pain in sickle cell disease can vary enormously thereby 
requiring a number of different approaches. Ideally the 
choice of drug should be influenced by an individual’s 
analgesic history and some patients may carry cards with 
details of their ideal analgesic regimen (Okpala and Tawil, 
2002; Rees et al, 2003). Paracetamol and non-steroidal 
anti-inflammatory drugs (NSAIDs) are appropriate for 
mild to moderate pain. If they are not effective then 
oral or parenteral opiates can be used. Patients can also 
benefit from some non-pharmacological approaches 
such as psychological support, massage, acupuncture, 
and transcutaneous electrical nerve stimulation.
Distraction and entertainment can be valuable and 
include television, video games, repeating inspirational 
phrases, and mental calculations. Studies have suggested 
that cognitive behavioural therapy for chronic pain can 
teach patients coping strategies that are also useful for 
acute pain (Thomas et al, 2001).
It is also important to treat predisposing elements 
alongside the management of pain. Factors such as diet, 
poor housing, inadequate heating, lack of education, 
n
n
poor access to expert services, and lifestyle choice may 
contribute to crises (Westerdale and Jedege, 2004).
Blood transfusion
Although anaemia is a constant feature of sickle cell 
disease, transfusion is rarely justified for chronic anaemia 
alone. Transfusion may be required in sickle cell disease 
either as an emergency measure or to prevent short and 
long-term complications. Transfusion therapy should be 
used judiciously because of risks such as:
Iron overload
Exposure to hepatitis
HIV and other infectious agents
Alloimmunization
Induction of hyperviscosity
Limitations on resources.
Transfusion can either be a simple top up or a blood 
exchange depending on the complications and available 
resources. The indications for having a blood transfusion 
n
n
n
n
n
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Preventing sickle cell crises in school children:
n Make the teachers and other staff aware of sickle cell disease.
n Painful episodes may be prevented by not allowing a child to 
become over heated or exposed to cold temperatures. A child 
should always be kept dry and warm.
n Prevent dehydration and encourage plenty of fluid consumption. 
Let the child have a water bottle with them or allow frequent 
water breaks. Extra fluid intake and the fact that the kidneys are 
sometimes affected by sickle cell disease means the child may need 
bathroom breaks more often than usual. Teachers should be made 
aware of this.
n Avoid strenuous activities. Anaemia can cause a child with sickle cell 
disease to tire before others and a rest period may be appropriate. 
Encourage participation in gym and sports activities but allow a child 
to stop without attracting undue attention. 
n A child should only swim in a heated pool and get dry immediately 
upon coming out. In some cases swimming should be  
avoided altogether.
n A child may be absent because of severe pain episodes which can 
require hospital admission. Support should be given for school work 
during hospital stays caused by prolonged complications. Children 
need to go to hospital regularly for follow up.
n Children may have a shorter stature and delayed puberty. The slow 
rate of growth is caused by a shortage of red blood cells. Taking the 
vitamin folic acid daily helps to make new red cells.
n Sickle cell disease does not affect intelligence but various problems 
arising from this lifelong illness may impair academic performance. 
These should be identified and addressed as they would for any 
child with difficulties.
Sources: The Sickle Cell Information Centre, 2002; The Learning Trust, City and 
Hackney Teaching Primary Care Trust, 2006; Oni et al, 2006
Table 2. Practical advice
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or exchange are recurrent painful vaso-occlusive crises 
with long hospital admissions, acute chest syndrome, 
stroke, priapism, and leg ulcers. Blood transfusion or 
exchange also can be performed before major operations, 
such as hip replacement because of avascular necrosis of 
the hip bone (Vichinsky, 2002; Sickle Cell Society, 2008).
Hydroxyurea
Hydroxyurea is a safe and effective therapy for children 
and adults with sickle cell anaemia. It mainly works 
by increasing the level of fetal haemoglobin in the red 
blood cells thereby reducing the concentration of sickle 
haemoglobin and sickling itself (Charache et al, 1995; 
Vichinsky, 2002). Research shows that patients receiving 
hydroxyurea had a lower incidence of painful events 
and acute chest syndrome as well as a reduced need 
for transfusion and hospitalization compared to those 
receiving no treatment (Charache et al, 1995; Kinney et 
al, 1999). Hydroxyurea can be used as an alternative to 
regular blood transfusion.
Some practical advice on how to help prevent sickle cell 
crises in school children can be found in Table 2.
Conclusion
It is important that school nurses have a good 
understanding of the condition to be able to offer the 
best possible support and information to the child or 
young person affected by the condition, peers, parents or 
carers, and other school employees. BJSN
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